Evaluation of prognostic parameters of E-cadherin status in breast cancer treatment

• Autorzy: Brzozowska A. , Sodolski T. , Duma D. , Mazurkiewicz T. , Mazurkiewicz M.
• Języki publikacji: EN

Abstrakty

EN

Introduction and objective. Breast cancer is one of the most frequent malignancies in women. Axillary lymph node involvement, tumour size, receptor status, and level of malignancy are the most significant prognostic factors in breast cancer, but insufficient to date. More factors are needed for establishing the prognosis and treatment in these patients. The aim of the presented study was evaluation of E- cadherin expression and its prognostic value among 89 specimens of breast cancer. Materials and methods. 89 formalin-fixed and paraffin-embedded breast cancer specimens were studied for expression of E-cadherin detected by immunohistochemistry. During 10-year observation overall/OS/and disease-free survival/DFS/ of patients were assessed. Results. Average of OS and DFS were shorter among patients without expression of E-cadherin in comparison to survival time of patients with expression of E-cadherin. The lack of E-cadherin expression was present more often among patients with distant metastasis. No essential changes were noticed in the level of E-cadherin depending on the size of the tumour, G, presence of metastasis into the lymph nodes, ER, PR and HER-2, hormonal condition and presence of cancerous tissues in lymphatic vessels and the infiltration of lymph nodes capsules.

• Wydawca: -
• Czasopismo: Annals of Agricultural and Environmental Medicine
• Rocznik: 2012
• Tom: 19
• Numer: 3
• Opis fizyczny: p.541-546,fig.,ref.

Twórcy

autor

Brzozowska A.

• Department of Oncology, Medical University in Lublin, Poland

autor

Sodolski T.

• Cardiology Department, Medical University in Lublin, Poland

autor

Duma D.

• Department of Laboratory Diagnostic, Medical University in Lublin, Poland

autor

Mazurkiewicz T.

• Orthopedics and Traumatology Department, Medical University in Lublin, Poland

autor

Mazurkiewicz M.

• Orthopedics and Traumatology Department, Medical University in Lublin, Poland

Bibliografia

• 1. Cowin P, Rowlands TM, Hatsell S J, et al. Cadherins and catenins in breast cancer. Curr Opin Cell Biol. 2005; 17: 499-508.
• 2. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science 1991; 251; 1451-1455.
• 3. Gumbinger B M. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996; 84, 345-357.
• 4. Brakebusch C, Bouvard D, Stanchi F. Integrins in invasive growth. J Clin Invest. 2002; 109: 999-1006.
• 5. Kowalski P J, Rubin M A, Kleer C G. E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res.2003; 5 (6): R217-R222.
• 6. Tang DG, Honn K V. Adhesion molecules and tumor metastasis: an update. Invasion Metastasis. 1995; 14: 109-122.
• 7. Okegawa T, Pong RC, Li Y, et al. The role of cell adhesion molecule in cancer progression and its application in cancer theraphy. Acta BiochimPol 2004; 51 (2): 445-457.
• 8. Ahmad IR, Hart IR. Mechanism of metastasis. Crit Rev Oncol Hematol 1997; 26 (3): 163-173.
• 9. Jeschke U, Mylonas I, Kuhn C. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymphnode metastases, their distant metastases, carcinomas with recurrenceand in recurrence. Anticancer Res. 2007; 27 (4A): 1969-1974.
• 10. Larue L, Ohsugi M, Hirchenhain J, et al. E-cadherin nullmutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad SciU S A 1994; 91: 8263-8267.
• 11. Frixen UH, Behrens J, Sachs M, et al. E-cadherin mediatedcell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol.1991; 113: 173-185.
• 12. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostatecancer. Cancer Res. 1994; 54: 3929-3933.
• 13. Umbas R, Isaacs WB, Bringuier PP, et al. Relation between aberrant alpha-catenin expression and loss of E-cadherin function in prostatecancer. Int J Cancer.1997; 74: 374-377.
• 14. Mayer B, Johnson JP, Leitl F, et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellulardedifferentiation and glandular disintegration. Cancer Res. 1993; 53:1690-1695.
• 15. Dorudi S, Hanby AM, Poulsom R, et al. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer. 1995; 71: 614-616.
• 16. A Batistatou, D Peschos, H Tsanou, et al. In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin. Br J Cancer. 2007; 7;96 (9): 1404-1408.
• 17. Shiozaki H, Kobayashi K, et al. Expression of E-cadherincell adhesion molecules in human breast cancer tissues and its relationship tometastasis. Cancer Res. 1993; 53: 1696-1701.
• 18. Charpin C, Garcia S, Bonnier P, et al. Reduced E-cadherin immunohistochemical expression in node-negative breast carcinomas correlateswith 10-year survival. Am J Clin Pathol. 1998; 109: 431-438.
• 19. Guriec N, Marcellin L, Gairard B, et al. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survi val.Invasion Metastasis. 1996; 16: 19-2.
• 20. Heimann R, Lan F, McBirde R, et al. Separating favorablefrom unfavorable prognostic markers in breast cancer: the role of E-cadherin. Cancer Res. 2000; 60: 298-304.
• 21. Siitonen SM, Kononen JT, Helin HJ, et al. Reduced Ecadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol.1996; 105: 394-402.
• 22. De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherinand catenins in invasive lobular breast cancer and lobular carcinoma in situ.J Pathol. 1997; 183: 404-411.
• 23. Gamallo C, Palacios J, Suarez A, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breastcarcinoma. Am J Pathol. 1993; 142: 987-993.
• 24. Moll R, Mitze M, Frixen UH, et al. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am JPathol. 1993; 143: 1731-1742.
• 25. Goldstein NS. Does the level of E-cadherin expression correlate with the primary breast carcinoma infiltration pattern and type of systemicmetastasis? Am J Clin Pathol. 2002; 118: 425-434.
• 26. Lipponen P, Saarelainen E, Ji H, et al. Expression of E-cadherin as related to other prognostic factors and survival in breast cancer. JPathol. 1994;174: 101–109.
• 27. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest. 1995; 72 (5): 506–512.
• 28. Parker C, Rampaul RS, Pinder SE, et al. E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer. 2001; 85 (12): 1958–1963.
• 29. Rubin MA, Mucci NR, Figurski J, et al. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarraytechnology. Hum Pathol. 2001; 32: 690-697.
• 30. Suciu C, Cîmpean AM, Mureşan AM, et al. E-cadherin expression in invasive breast cancer. Rom J Morphol Embryol. 2008; 49 (4): 517–523.
• 31. Nikiel B, Chekan M, Jaworska M, et al. Expression of the selected adhesive molecules (cadherin E, CD44,LGAL3 and CA50) in papillarythyroid carcinoma. Pol J Endocrinol. 2006; 57 (4): 32-37.
• 32. Qureshi H, Linden M, Divine G, et al. E-cadherin Status in Breast Cancer Correlates With Histologic Type but Does Not Correlate WithEstablished Prognostic Parameters. Am J Clin Pathol. 2006; 125 (3):377-85.
• 33. Makdissi F, Machado L, Oliveira A. Expression of E-cadherin, Snail and Hakai in epithelial cells isolated from the primary tumor and from peritumoral tissue of invasive ductal breast carcinomas. Braz J MedBiol Res. 2009; 42 (12): 1128-1137.
• 34. Rakha EA, Abd El Rehim D, Pinder SE. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognosticsignificance. Histopathology 2005; 46 (6): 685-93.
• 35. Guriec N, Marcellin L, Gairard B, et al. E-cadherin mRNA expression in breast carcinomas correlates with overall and disease-free survival.Invasion Metastasis 1996; 16: 19-26.
• 36. Berezhnaya N, Belova O, Vinnichuk Y, et al. Expression of e-cadherin in drug resistant human breast cancer cells and their sensitivity tolymphokine-activated lymphocytes action Exp Oncol. 2009; 31 (4):242–245.
• 37. Heimann R, Lan F, McBride R, Hellman S. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.Cancer Res. 2000; 60 (2): 298–304.
• 38. Bukholm IR, Nesland JM, Bukholm G. Expression of adhesion proteins E-cadherin, alpha-catenin, beta-catenin and gamma-catenin is differentin T1 and T2 breast tumours. Pathology 2006; 38 (5): 403-7.
• 39. Da Silva BB, dos Santos Ar, Pires CG. E-cadherin expression in estrogen receptor-positive and negative breast carcinomas of postmenopausalwomen. Eur J Gynaecol Oncol. 2010; 31 (1): 90-3.
• 40. Mohammadizadeh F, Ghasemibasir H, Rajabi P. Correlation of E-cadherin expression and routine immunohistochemistry panel in breast invasive ductal carcinoma. Cancer Biomark. 2009; 5 (1): 1-8.

Uwagi

rekord w opracowaniu